NEXMED INC
			Symbol			NEXM

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

NexMed Provides Update on Anti-Fungal Product

2009-10-14 08:45 ET - News Release

Company to Appeal Nasdaq Delisting Decision

EAST WINDSOR, N.J. -- (Business Wire)

NexMed, Inc. (Nasdaq: NEXM), a developer of products based on the NexACT^® technology, today announced that it has completed its post hoc analysis of NM100060, the Company’s topically-applied treatment for onychomycosis, commonly known as nail fungus. Based on this analysis, NexMed seeks to pursue signing a partner for further development of the product.

NM100060 has previously been tested in approximately 2,000 patients enrolled in three Phase 3 clinical studies conducted by Novartis. On July 7, 2009, the Company announced the mutual decision with Novartis to terminate the exclusive, global licensing agreement for NM100060.

Vivian Liu, NexMed’s Chief Executive Officer said, “The recently completed analysis of the Novartis data indicates a real effect of treatment in certain patient populations and continues to support our conclusion about the product’s potential for treating patients with mild onychomycosis. With the lessons learned from the Novartis studies, we are convinced that additional Phase 3 studies can be successfully conducted which, we believe, will generate significant results. Toward that end, we are currently sharing, on a confidential basis, NexMed’s highly extensive and proprietary clinical database with potential partners interested in licensing NM100060 for further development.”

The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try, click here for a free 30 day trial subscription.